AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo

Cancer Gene Therapy

Volumn 11, Issue 1, 2004, Pages 73-80

  Zacchigna, Serena ^a   Zentilin, Lorena ^a   Morini, Monica ^b   Dell'Eva, Raffaella ^b   Noonan, Douglas M ^b   Albini, Adriana ^b   Giacca, Mauro ^a,c  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SCUOLA NORMALE SUPERIORE   (Italy)

Author keywords

AAV; Angiogenesis; MMPs; Tumor growth

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; BETA GALACTOSIDASE; COMPLEMENTARY DNA; GELATINASE A; GELATINASE B; MATRIGEL; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADENO ASSOCIATED VIRUS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; CANCER INHIBITION; CELL DEATH; CELL INVASION; CELL MIGRATION; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; INOCULATION; KAPOSI SARCOMA; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; BASEMENT MEMBRANE; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; DEPENDOVIRUS; ENDOTHELIAL CELLS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA, KAPOSI; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0347356412     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700657     Document Type: Article

References (35)

1. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000;6:4823-4830.
2. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58-61.
3. Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-174.
5. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 2001;11:143-152.
6. DeClerck YA, Imren S, Montgomery AM, et al. Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol. 1997;425:89-97.
7. Murphy G, Cawston TE, Reynolds JJ. An inhibitor of collagenase from human amniotic fluid. Purification, characterization and action on metalloproteinases. Biochem J. 1981;195:167-170.
8. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999;103:1237-1241.
9. Bloomston M, Shafii A, Zervos EE, Rosemurgy AS. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res. 2002;102:39-44.
10. Kawamata H, Kawai K, Kameyama S, et al. Overexpression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer. 1995;63:680-687.
11. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 1999;59:6267-6275.
12. Yamauchi K, Ogata Y, Nagase H, Shirouzu K. Inhibition of liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP-1 gene into KM 12SM cells. Surg Today. 2001;31:791-798.
13. Rigg AS, Lemoine NR. Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther. 2001;8:869-878.
14. Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood. 1998;92:1342-1349.
15. Albini A, Paglieri I, Orengo G, et al. The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS. 1997;11:713-721.
16. Bussolino F, Arese M, Montrucchio G, et al. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest. 1995;96:940-952.
17. Marchisone C, Del Grosso F, Masiello L, et al. Phenotypic alterations in Kaposi's sarcoma cells by antisense reduction of perlecan. Pathol Oncol Res. 2000;6:10-17.
18. Cassoni P, Sapino A, Deaglio S, et al. Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross-talk. Cancer Res. 2002;62:2406-2413.
19. Zentilin L, Marcello A, Giacca M. Involvement of cellular double-strand DNA break-binding proteins in processing of recombinant adeno-associated virus (AAV) genome. J Virol. 2001;75:12279-12287.
20. Albini A, Fontanini G, Masiello L, et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS. 1994;8:1237-1244.
21. Albini A, Marchisone C, Del Grosso F, et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol. 2000;156:1381-1393.
22. Cai T, Fassina G, Morini M, et al. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest. 1999;79:1151-1159.
23. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 1997;3:306-312.
24. Snyder RO, Spratt SK, Lagarde C, et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther. 1997;8:1891-1900.
25. Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon? Gene Therapy. 2000;7:24-30.
26. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002;21:2245-2252.
27. Cesarman E, Mesri EA, Gershengorn MC. Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? J Exp Med. 2000;191:417-422.
28. Harris AL. Antiangiogenesis for cancer therapy. Lancet. 1997;349:S1113-S1115.
29. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 2002;16:2-14.
30. Toschi E, Barillari G, Sgadari C, et al. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell. 2001;12:2934-2946.
31. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19:6642-6650.
32. Bergers G, Javaherian K, Lo KM, et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999;284:808-812.
33. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA. 1983;80:3734-3737.
34. Marchisone C, Benelli R, Albini A, et al. Inhibition of angiogenesis by type I interferons in models of Kaposi's sarcoma. Int J Biol Markers. 1999; 14:257-262.
35. Deodato B, Arsic N, Zentilin L, et al. Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Therapy. 2002;9:777-785.